Display options
Share it on

Contemp Clin Trials Commun. 2021 Feb 06;21:100733. doi: 10.1016/j.conctc.2021.100733. eCollection 2021 Mar.

A randomized double-blind controlled trial of everolimus in individuals with .

Contemporary clinical trials communications

Antonio Y Hardan, Booil Jo, Thomas W Frazier, Patricia Klaas, Robyn M Busch, Kira A Dies, Rajna Filip-Dhima, Anne V Snow, Charis Eng, Rabi Hanna, Bo Zhang, Mustafa Sahin

Affiliations

  1. Department of Psychiatry and Behavioral Science, Stanford University, Stanford, CA, USA.
  2. Autism Speaks, New York, NY, USA.
  3. Department of Psychology, John Carroll University, Cleveland Heights, Ohio, USA.
  4. Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  5. Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
  6. Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA.
  7. Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  8. F.M. Kirby Neurobiology Center, Translational Neuroscience Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  9. Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  10. Department of Pediatric Hematology Oncology and Bone Marrow Transplantation, Cleveland Clinic Children's Hospital, Cleveland, OH, USA.
  11. Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  12. Germline High Risk Cancer Focus Group, Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.

PMID: 33644493 PMCID: PMC7887633 DOI: 10.1016/j.conctc.2021.100733

Abstract

This randomized, double-blind controlled trial of everolimus in individuals with germline phosphatase and tensin homolog mutations (

© 2021 The Author(s).

Keywords: Autism spectrum disorder; Everolimus; Neurobehavior and neurocognition; PTEN hamartoma tumor syndrome; Randomized controlled trial

Conflict of interest statement

Authors declare no conflict of interest.

References

  1. J Neurosci. 2009 Feb 11;29(6):1773-83 - PubMed
  2. J Clin Invest. 2019 Feb 1;129(2):452-464 - PubMed
  3. Am J Med Genet A. 2007 Mar 15;143A(6):589-93 - PubMed
  4. Mol Psychiatry. 2016 Jan;21(1):118-25 - PubMed
  5. Cold Spring Harb Perspect Med. 2019 Oct 1;9(10): - PubMed
  6. Recent Results Cancer Res. 2007;172:99-124 - PubMed
  7. Nat Genet. 2001 Dec;29(4):404-11 - PubMed
  8. Neurology. 2019 Apr 16;92(16):e1912-e1925 - PubMed
  9. Neurotherapeutics. 2015 Jul;12(3):609-19 - PubMed
  10. Sci Transl Med. 2016 Jan 13;8(321):321ra5 - PubMed
  11. Ann Clin Transl Neurol. 2017 Nov 12;4(12):877-887 - PubMed
  12. Eur J Hum Genet. 2011 Jul;19(7):763-8 - PubMed
  13. J Neurodev Disord. 2013 Sep 16;5(1):24 - PubMed
  14. Hum Mol Genet. 2014 Jun 15;23(12):3212-27 - PubMed
  15. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12923-8 - PubMed
  16. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1989-94 - PubMed
  17. Epilepsia. 2002 Dec;43(12):1551-8 - PubMed
  18. J Neurosci. 2012 Apr 25;32(17):5880-90 - PubMed
  19. Transl Psychiatry. 2019 Oct 8;9(1):253 - PubMed
  20. Genet Med. 2013 Jul;15(7):548-53 - PubMed
  21. Schizophr Bull. 1998;24(1):163-74 - PubMed
  22. Neuron. 2006 May 4;50(3):377-88 - PubMed
  23. Annu Rev Med. 2020 Jan 27;71:103-116 - PubMed
  24. Disabil Rehabil. 1995 Jul;17(5):217-24 - PubMed
  25. J Child Adolesc Psychiatr Ment Health Nurs. 1991 Oct-Dec;4(4):127-31 - PubMed
  26. Mol Psychiatry. 2015 Sep;20(9):1132-8 - PubMed
  27. J Med Genet. 2005 Apr;42(4):318-21 - PubMed

Publication Types

Grant support